Abstract
Imatinib mesylate (STI571) is a new therapeutic agent which inhibits the tyrosine kinase of the BCR-ABL, c-kit and platelet derived growth factor oncogenes. It is used for the treatment of chronic myelogenous leukemia, Philadelphia chromosome positive acute lymphoblastic leukemia and gastrointestinal stromal tumors. Although, cutaneous side effects of this drug is common, lichenoid eruption is exceptional. We report two cases of disseminated lichenoid cutaneous reaction, which developed in two patients with chronic myelogenous leukemia treated with imatinib mesylate.
Highlights
Imatinib is a 2- phenylaminopyrimidine derivative that shows inhibiting effect on epidermal growth factor receptor tyrosine kinase activity. It has been shown remarkable clinical activity in chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans and hypereosinophilic syndrome (HES) by inhibiting the tyrosine kinase activities of bcr-abl fusion protein, c-kit oncogene, platelet derived growth factor receptor alpha (PDGFRA) and the mutated genes involving in HES respectively (1,2)
We report two cases of lichenoid drug eruption associated with imatinib mesylate
The most common toxicities associated with this drug are mild nausea (70%) and diarrhea (56%)
Summary
Imatinib is a 2- phenylaminopyrimidine derivative that shows inhibiting effect on epidermal growth factor receptor tyrosine kinase activity. Lichenoid eruption to imatinib is a rarely seen cutaneous adverse event (4). We report two cases of lichenoid drug eruption associated with imatinib mesylate. Five weeks after the initiation of therapy; he presented with the complaints of severe itching and disseminated skin eruption.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
